CDER Ombudsman Referees Increasing Number Of Internal Scientific Disputes
Last year, Virginia Behr, the ombudsman for FDA's Center for Drug Evaluation and Research, dealt with the usual consumer and industry complaints about off-label drug promotion, marketing of unapproved drugs and unethical research conduct. But she also played a greater role mediating scientific disputes between FDA staff
You may also be interested in...
Purdue's reformulated OxyContin could face generics in 2013 unless FDA withdraws the initial NDA because of safety concerns.
FDA's oversight of clinical trials didn't reach the headlines during coverage of the Senate Finance Committee's report on Avandia safety, but pressure on the agency from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, could have far-reaching consequences for how industry conducts research for products in the future
FDA will have to balance the goal of preventing liver injury with concerns about access to treatment and narcotic abuse as it weighs whether to implement a joint advisory committee's narrow recommendation to remove acetaminophen from combination Rx products